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Summary
Background:  Tranexamic  acid  decreases  total  blood  loss  after  total  hip  arthroplasty  (THA).
Total blood  loss  is  the  sum  of  external  bleeding  and  bleeding  into  tissues,  i.e.,  haematomas.
Haematomas  may  cause  acute  or  even  chronic  postoperative  pain.
Hypothesis:  Tranexamic  acid  decreases  haematomas,  thereby  diminishing  postoperative  pain
after THA.
Methods:  In  a  retrospective  matched  case-control  study,  patients  receiving  tranexamic  acid
(15 mg/kg,  before  the  incision  and  again  at  skin  closure)  were  compared  to  controls  not  given
tranexamic  acid.  Matching  was  on  sex,  surgeon,  and  peri-operative  analgesics  (ketamine,  keto-
profen, pregabalin,  and  nefopam).  Standardised  protocols  were  used  for  anaesthesia,  analgesia,
and blood  sparing.  Haematoma  volume  was  computed  as  the  difference  between  total  blood
loss (estimated  from  the  erythrocyte  counts  on  days  —1  and  +5)  and  measured  external  blood
loss. Patients  were  monitored  from  D0  to  D7  then  interviewed  by  telephone  on  D30,  D90,  and
D180. To  detect  a  30%-decrease  in  the  morphine  dose  at  H24  (criterion  1)  and  D7  (criterion  2)
and a  20%  decrease  in  haematoma  volume  on  D5  (criterion  3),  the  required  numbers  of  patients
were 90,  90,  and  77,  respectively;  therefore,  95  patients  were  included.∗ Corresponding author. Tel.: +33 2 47 47 85 51;
fax: +33 2 47 47 46 60.
E-mail address: f.remerand@chu-tours.fr (F. Remérand).
1877-0568/$ – see front matter © 2013 Published by Elsevier Masson SAS.
http://dx.doi.org/10.1016/j.otsr.2013.03.029
668  F.  Remérand  et  al.
Results:  Tranexamic  acid  decreased  haematoma  volume  by  30%  (351  ±  254  mL  versus
247 ±  189  mL  erythrocytes,  P  =  0.002),  had  no  effect  on  morphine  consumption  at  H24
(12 ±  11  mg  versus  14  ±  12  mg,  P  =  0.346),  increased  morphine  consumption  on  D7  (26  ±  24  mg
versus 35  ±  36  mg,  P  =  0.029),  and  had  no  effect  on  long-term  pain.
Discussion:  After  THA,  tranexamic  acid  decreases  haematoma  volume  without  improving  anal-
gesia.
Level of  evidence:  3  (case-control  study).
© 2013  Published  by  Elsevier  Masson  SAS.
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urgery  is  followed  by  acute  and  chronic  pain.  Although
bout  100  000  patients  undergo  primary  THA  each  year
n  France,  the  contribution  of  haematomas  to  acute  and
hronic  postoperative  pain  is  unclear.  Haematomas  may
ause  pain  via  local  compression  and/or  via  the  inﬂamma-
ory  process  needed  to  achieve  their  resorption.
Tranexamic  acid  is  an  antiﬁbrinolytic  agent.  When  given
ntravenously  during  surgery,  tranexamic  acid  diminishes
otal  blood  loss  and  blood  transfusion  requirements  after
HA,  apparently  without  increasing  the  risk  of  thrombosis
1,2].  Total  blood  loss  is  the  sum  of  external  bleeding  (surgi-
al  ﬁeld  and  drains)  and  hidden  bleeding  (haematomas  and
lood  inﬁltrating  the  tissues  around  the  surgical  site).  No
tudies  have  evaluated  the  effect  of  tranexamic  acid  on
aematoma  volume  after  THA.
Our  objective  in  this  study  was  to  evaluate  whether
ranexamic  acid  decreased  postoperative  haematoma  vol-
me  after  THA  and  whether  this  effect,  if  demonstrated,
as  associated  with  decreased  pain.
ethods
atients
e  conducted  a  retrospective  single-centre  case-control
tudy  using  a  database  including  consecutive  adults  who
nderwent  primary  THA  between  January  2007  and  May
011  in  a  teaching  hospital  department.  Exclusion  criteria
ere  absence  of  data  on  the  main  evaluation  criteria  and/or
atching  criteria;  contra-indication  to  tranexamic  acid
thromboembolic  event  in  the  past  6  months,  thrombophilia,
oronary  angioplasty,  cerebrovascular  event,  peripheral
rterial  disease  stage  III-IV,  creatinine  clearance  less  than
0  mL/min,  or  epilepsy);  contra-indication  to  paracetamol
allergy  or  porphyria);  inability  of  the  patient  to  self-assess
ain  intensity  on  a  numeric  rating  scale  (NRS)  from  0  (no
ain)  to  10  (worst  pain  imaginable);  inability  of  the  patient
o  use  a  patient-controlled  analgesia  device;  and  preoper-
tive  pain  requiring  more  than  20  mg  morphine  equivalent
er  day.
naesthesiaremedication  was  with  0.5  mg  alprazolam  before  2009  and
0  to  150  mg  pregabalin  (depending  on  renal  function  and
ge)  thereafter.
h
aPatients  were  monitored  for  ECG,  blood  pressure,  oxy-
en  saturation,  neuromuscular  blockade,  blood  gas  values,
nd  oesophageal  temperature.  A  forced-air  warming  blan-
et  was  used  to  maintain  body  temperature.  All  THA
rocedures  were  performed  under  general  anaesthesia
nduced  with  0.2—0.4  g/kg  sufentanil,  2—3  mg/kg  propo-
ol,  and  0.5  mgkg  atracurium.  Orotracheal  intubation  was
hen  performed  and  anaesthesia  maintained  with  inhaled
evoﬂurane  and  nitrous  oxide.  Repeat  injections  of  sufen-
anil  or  atracurium  and  the  use  of  intravenous  ephedrine,
tropine,  and  ﬂuids  were  at  the  discretion  of  the  anaesthe-
iologist  in  charge  of  the  patient.
perative  technique
ll  patients  were  in  the  lateral  decubitus  position.  Various
urgical  approaches  and  prosthesis  types  (cemented  or  unce-
ented)  were  used.  All  THA  procedures  were  performed
y,  or  under  direct  supervision  by,  an  orthopaedic  surgeon
ellow  or  university-hospital  orthopaedic  surgeon.
nalgesia
 0.5  mg/kg  ketamine  bolus  injected  shortly  before  the  inci-
ion  was  followed  by  a  continuous  infusion  (2  g/kg/min)  for
4  hours  [3,4].
At  the  end  of  the  THA  procedure,  the  patient  was
iven  an  injection  of  paracetamol  1  g  and  ketoprofen  50  mg
in  the  absence  of  contra-indications:  creatinine  clear-
nce  <  30  mL/min,  history  of  gastro-duodenal  ulcer,  allergy,
r  thrombocytopenia  <  100  000/mm3).  Paracetamol  ther-
py  was  continued  throughout  the  hospital  stay  (3—4  g per
ay)  and  ketoprofen  therapy  for  48  hours  (200  mg  per  day).
efopam  was  used  also  (120  mg  per  day  for  48  hours)  in  2008
nd  pregabalin  bid  for  ﬁve  days  thereafter.
In  the  post-anaesthesia  care  unit,  morphine  titration
as  performed  in  patients  with  NRS  scores  greater  than  3
2—3  mg  IV  every  ﬁve  minutes  until  the  NRS  fell  below  4  or
ide  effects  developed).  All  patients  then  received  patient-
ontrolled  analgesia  with  morphine—droperidol  (1-mg  bolus,
-minute  refractory  period,  maximal  dose  of  20  mg/4  hours)
or  at  least  24  hours,  followed  by  oral  morphine  sulphate
20  mg  if  NRS  score  >  3).
Episodes  of  nausea  or  vomiting  were  managed  with  4  mgPain  intensity  was  evaluated  at  the  bedside  during  the
ospital  stay  then  during  telephone  interviews  (D30,  D90,
nd  D180)  using  a  standardised  questionnaire  [4]. In  patients
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not  available  for  interview  on  D180,  the  D90  data  were  used
instead  of  the  D180  data  in  the  analysis.
Blood-sparing  strategy
We  used  a  previously  described  strategy  [5,6].  Oral  iron  and
folic  acid  supplements  were  given  preoperatively,  as  well  as
two  to  three  human  recombinant  erythropoietin  injections
in  patients  whose  haematocrit  was  less  than  39%  at  the  pre-
anaesthesia  visit.
The  decision  to  use  tranexamic  acid  (Exacyl®,  Sanoﬁ-
Aventis  France,  Paris,  France)  was  at  the  discretion  of  the
anaesthesiologist  in  charge  of  the  patient.  Two  injections
(15  mg/kg  over  20  minutes)  were  given  at  the  beginning  and
at  the  end  of  anaesthesia.
Intra-operative  cell  salvage  was  very  rarely  used.  Start-
ing  in  2010,  intravenous  iron  was  given  postoperatively  in
patients  whose  haematocrit  was  less  than  33%.  Homologous
red-blood-cell  packs  were  transfused  if  the  haematocrit  fell
below  21%;  a  higher  cut-off  of  30%  was  used  when  clini-
cal  tolerance  of  the  anaemia  was  poor  and  in  patients  with
coronary  artery  disease  or  other  types  of  heart  disease.
Blood  cell  counts  and  serum  assays  of  electrolytes  and
creatinine  were  obtained  on  D—1,  D1,  and  D5.
Thromboprophylaxis  involved  a  daily  fondaparinux  injec-
tion  (2.5  mg)  starting  8  hours  after  surgery.  A  daily
enoxaparin  injection  (4000  IU)  was  used  instead  in  patients
with  a  creatinine  clearance  less  than  30  mL/min,  age  above
80  years,  or  body  weight  less  than  50  kg.
Statistical  analysis
The  main  evaluation  criteria  were  haematoma  volume
(taken  as  a  surrogate  for  blood  losses  into  tissues)  and
morphine  doses  at  H24  and  D7.  Haematoma  volume  was  esti-
mated  in  millilitres  of  red  blood  cells  by  subtracting  external
blood  loss  from  total  blood  loss  [7],  as  shown  in  Fig.  1.
In  the  736  evaluable  patients,  mean  total  blood  loss  was
535  ±  283  mL.  Assuming  a  haematoma  volume  equal  to  50%
of  total  blood  loss  (267  ±  141  mL),  77  patients  were  needed
in  each  group  to  detect  a  20%  decrease  in  haematoma  vol-
ume  with    set  at  0.05  and    at  0.10.
The  morphine  doses  administered  to  the  patients  were
converted  to  intravenous  equivalents  (30  mg  orally  =  20  mg
sub-cutaneously  =  10  mg  intravenously).  Mean  morphine
doses  used  in  our  department  were  10  ±  10  mg  on  H24  and
20  ±  20  mg  on  D7  (in  160  patients,  from  November  2007  to
August  2009,  given  paracetamol,  ketoprofen,  ketamine,  and
pregabalin).  To  detect  a  30%  decrease  in  morphine  doses  at
H24  and  D7,  90  patients  were  needed  in  each  group  with  
set  at  0.05  and    at  0.10.
We  decided  to  include  95  patients  in  each  group.
Matching
Each  control  not  given  tranexamic  acid  was  matched  to
a  case  given  tranexamic  acid  on  six  criteria:  sex,  sur-
geon,  nefopam,  ketoprofen,  pregabalin,  and  ketamine.  All
patients  received  paracetamol.  One  of  us  (MC)  matched
the  patients  using  a  database  of  736  anonymised  patients
containing  only  information  on  the  matching  criteria.  When
d
e
t669
everal  controls  were  identiﬁed  for  a  single  patient,  the  con-
rol  having  the  smallest  identiﬁcation  number  was  chosen.
xpression  of  data
ontinuous  quantitative  data  were  described  as  mean  ±  SD
nd  other  data  as  number  (%).  Quantitative  variables  were
ompared  using  Student’s  t  test  for  paired  data  and  qual-
tative  variables  using  Fisher’s  test.  Values  of  P  less  than
.05  were  considered  signiﬁcant.  The  statistical  analyses
ere  performed  using  PASW  Statistics  18  software  (SPSS  Inc.,
hicago,  IL,  USA).
esults
atients  and  procedures
n  each  group  of  95  patients  (55  women  and  40  men),
9  patients  received  ketoprofen,  87  ketamine,  25  nefopam,
nd  37  pregabalin.
No  statistically  signiﬁcant  baseline  differences  were
ound  between  the  two  groups  (Table  1).
During  surgery  (Table  2),  the  cases  received  smaller
mounts  of  crystalloids  and  vasoactive  agents  than  did  the
ontrols.  No  signiﬁcant  differences  were  found  between  the
wo  groups  for  the  intra-operative  surgical  data.  Although
he  operating  time  was  shorter  in  the  cases  than  in  the  con-
rols,  the  difference  failed  to  reach  statistical  signiﬁcance.
lood  losses
n  the  cases,  total  blood  loss  was  lower  by  28%  (P  <  0.001)  and
aematoma  volume  by  30%  (from  351  ±  254  to  247  ±  189  mL
ed  blood  cells,  P  =  0.002)  compared  to  the  controls,  and  the
ecreases  were  apparent  as  early  as  D1  (Table  3).
The  proportion  of  patients  with  clinical  haematomas  was
ot  signiﬁcantly  different  between  the  two  groups.  Intra-
perative  cell  salvage  was  used  in  two  patients,  both  in
he  control  group.  A  case  with  spondylo-epiphyseal  dysplasia
nderwent  drainage  of  a haematoma  on  D14;  the  ﬂuid  was
terile,  no  neurovascular  complications  were  recorded,  and
o  blood  transfusion  was  required.  A  patient  in  the  control
roup  experienced  deep  vein  thrombosis.
The  amount  of  morphine  used  by  H24  was  not  signiﬁcantly
ifferent  between  the  two  groups  (12  ±  11  mg  in  the  controls
nd  14  ±  12  mg  in  the  cases,  P  =  0.346)  (Table  4).  Morphine
onsumption  was  lower  in  the  controls  than  in  the  cases  at
48  and  on  D7  (26  ±  24  mg  versus  35  ±  36  mg,  P  =  0.029).
The  follow-up  data  showed  no  signiﬁcant  between  group
ifferences  in  hip  pain  at  rest,  hip  pain  while  walking,  or
unctional  recovery.
iscussion
n  this  retrospective  case-control  study,  tranexamic  acid
dministration  to  patients  undergoing  THA  decreased
aematoma  volume  by  30%  but  had  no  effect  on  early  or
elayed  postoperative  pain  intensity.
The  retrospective  design  is  a  limitation  of  our  study.  How-
ver,  the  individual  matching  of  cases  and  controls  limited
he  risk  of  bias  regarding  the  main  factors  known  to  inﬂuence
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Figure  1  Method  used  to  estimate  haematoma  volume.  Obesity  was  deﬁned  as  a  body  mass  index  (weight  in  kg/height  in  m
squares) greater  than  30  kg/m2.  Based  on  a  discussion  between  the  physicians  and  surgeons  in  charge  of  the  patients,  the  mean
amount of  blood  lost  by  aspiration  and  in  swabs  was  estimated  at  200  mL.  Blood  lost  through  drains  was  deﬁned  as  undiluted  blood
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qefore D1  (at  8:00  am)  and  blood  diluted  by  half  thereafter  (b
fter knee  arthroplasty  [7]).  mL:  millilitres.
ostoperative  pain  and  bleeding.  Thus,  paracetamol  [8],
etoprofen  [8],  ketamine  [4],  pregabalin  [9],  and  nefopam
used  alone)  [10]  have  been  reported  to  decrease  morphine
onsumption  after  THA.  Female  gender  was  associated  with
n  increased  risk  of  acute  postoperative  pain  [11].  The
urgeon  clearly  has  a  major  inﬂuence  on  both  pain  and
otal  blood  loss.  Control  of  this  last  variable  is  better  in
 case-control  study  than  with  a  randomised  design,  which
ever  involves  stratiﬁcation  on  surgeons.  An  effect  of  non-
teroidal  anti-inﬂammatory  drugs  on  haemostasis  has  been
ocumented  after  tonsillectomy  [12]  but  remains  controver-
ial  in  orthopaedic  surgery.  Finally,  matching  allowed  us  to
btain  two  groups  exhibiting  similar  pre-  and  intra-operative
haracteristics.Our  study  conﬁrms  that  tranexamic  acid  decreases  total
lood  loss  during  THA.  Homologous  blood  transfusion  is
arely  used  in  THA  (8%  versus  3%)  and,  therefore,  the  statis-
ical  power  for  detecting  a  difference  in  this  variable  is  low.
m
d
T
h on  the  dilutions  of  0.84  before  D1  and  0.58  after  D1  reported
he  beneﬁts  of  tranexamic  acid  seem  to  start  early,  during
he  surgical  procedure,  since  the  need  for  vasoactive  agents
nd  intravenous  volume  repletion  are  diminished.  Finally,
he  lower  serum  creatinine  level  on  D5  in  the  tranexamic-
cid  group  may  reﬂect  greater  stability  of  blood  volume.
he  use  of  tranexamic  acid  may  decrease  the  operating  time
Table  2, p  =  0.053).  Easier  haemostasis  and  better  visibility
f  the  operative  ﬁeld  may  explain  this  ﬁnding.
We  found  that  tranexamic  acid  therapy  was  associated
ith  a  30%  decrease  in  haematoma  volume,  as  early  as  D1
nd  until  D5.  Nevertheless,  the  proportion  of  patients  with
linical  haematomas  was  not  signiﬁcantly  diminished  (27%
ersus  16%,  P  =  0.108),  a fact  that  probably  reﬂects  inade-
uate  statistical  power.  The  use  of  postoperative  drainage
ay  have  decreased  the  overall  rate  of  haematomas,
espite  controversy  about  the  efﬁcacy  of  this  measure  [13].
herefore,  tranexamic  acid  therapy  may  be  particularly
elpful  when  drainage  is  not  used.
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Table  1  Baseline  characteristics  of  the  95  controls  and  the  95  cases  treated  with  tranexamic  acid.
Controls  Cases  P
Patients
Age  (years)  65  ±  11  63  ±  14  0.286
Body mass  index  28  ±  5  27  ±  5  0.861
ASA III-IV  score  5  (5)  8  (8)  0.567
History of  hypertension  42  (44)  35  (37)  0.375
History of  diabetes 12  (13) 4  (4) 0.065
Hip OA-dysplasia-other 62  (65)-15  (16)-18  (19) 54  (57)-12  (13)-29  (30) 0.177
Haemoglobin  level  (g/dL) 14.0  ±  1.7 14.1  ±  1.2 0.681
NRS at  rest  on  D—1a 4.5  ±  2.8  4.3  ±  3.2  0.613
NRS while  walking  on  D-1a 6.7  ±  2.3  6.4  ±  2.4  0.277
Preoperative  treatment
Antidepressants  14  (15)  7  (7)  0.164
Benzodiazepines  and/or  hypnotics 15  (16) 18  (19) 0.702
Opioidsb 36  (38) 26  (28) 0.162
ASA: American Society of Anesthesiologists score; OA, osteoarthritis; NRS, numeric rating scale (used to score pain in the operated hip).
The data are mean ± SD or n (%).
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rMissing for six patients in each group.
b Tramadol, dextropropoxyphene, or morphine < 20 mg per day; 
Although  haematoma  size  decreased,  no  improvement
in  postoperative  analgesia  was  seen  in  the  tranexamic
acid  group  compared  to  the  controls.  Most  of  the  patients
received  multimodal  analgesia  with  three  to  four  non-opioid
analgesics.  This  fact  explains  the  low  levels  of  morphine
consumption.  However,  the  study  was  powered  to  detect
a  30%-decrease  in  morphine  consumption  at  H24  in  this  sit-
uation.  The  absence  of  an  effect  on  pain  cannot  be  ascribed
to  the  use  of  an  inadequate  dosage  of  tranexamic  acid:  we
used  the  same  dosage  as  in  most  of  the  previously  reported
protocols  [2].
Our  ﬁndings  after  THA  are  similar  to  those  reported
previously  after  knee  arthroplasty  [7].  They  suggest  that,
after  THA,  haematomas  contribute  only  a  small  proportion
of  total  postoperative  pain.  Alternatively,  the  decrease  in
haematoma  volume  achieved  by  using  tranexamic  acid  may
m
p
c
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Table  2  Intra-operative  characteristics  of  the  95  controls  and  th
Controls  
Anaesthesia
Sufentanil  (g/kg)  1.0  ±  0.4  
Core body  temperature  at  closure  (◦C)a 35.9  ±  0.6  
Need for  vasoactive  agents  69  (73)  
Colloids (mL)b 339  ±  323  
Crystalloids  (mL)  1179  ±  495  
Surgery
THA on  the  left  side  38  (40)  
Operating time  (minutes)  138  ±  104  
Cemented cup  64  (67)  
Cemented stem  61  (64)  
Bauer-Moore-trochanterotomy  31  (33)-55  (
The data are mean ± SD or n (%).
a Data missing for three patients in each group
b Data missing for two patients in each groupng for one case and two controls.
ave  been  too  small  to  signiﬁcantly  affect  pain  (104  mL  of
ed  blood  cells  is  equivalent  to  300—400  mL  of  blood  based
n  the  haematocrit).  The  number  of  patients  with  diabetes
r  antidepressant  therapy  was  higher  in  the  control  group
han  in  the  case  group.  However,  a  confounding  effect  of
hese  two  factors  is  unlikely,  as  the  differences  were  not  sig-
iﬁcant,  the  prevalence  was  less  than  15%,  and  diabetes  can
nduce  either  hyperalgesia  or  hypoesthesia.  The  increased
orphine  consumption  noted  on  D7  in  the  cases  may  be
scribable  to  hyperalgesia  induced  by  tranexamic  acid,  as
pplication  of  tranexamic  acid  to  the  spinal  cord  has  been
eported  to  induce  hyperalgesia  in  an  anaesthetised  rat
odel  [14]. Unfortunately,  this  effect  was  not  sought  in  our
atients.  The  small  increase  in  morphine  consumption  in  the
ases  (9  mg)  had  no  impact  on  pain  scores,  morphine-related
ide  effects,  functional  recovery,  or  delayed  pain  after  THA.
e  95  cases  treated  with  tranexamic  acid.
Cases  P
1.0  ±  0.3  0.321
36.0  ±  0.6  0.503
51  (54)  0.010
333  ±  279  0.897
1053  ±  346  0.046
43  (45)  0.557
120  ±  31  0.053
58  (61)  0.449
57  (60)  0.654
58)-9  (9)  33  (35)-54  (57)-8  (8)  0.937
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Table  3  Blood  losses.
Controls  Cases  P
Blood  losses
Total,  D0—D5  (mL  RBCs)  565  ±  296  409  ±  228  <  0.001
Total, D0—D1  (mL  RBCs)  426  ±  207  330  ±  142  <  0.001
Total, D1—D5  (mL  RBCs)  156  ±  191  100  ±  125  0.024
Haematomas,  D0—D5  (mL  RBCs)  351  ±  254  247  ±  189  0.002
Haematomas,  D0—D1  (mL  RBCs)  212  ±  150  161  ±  123  0.005
Haematomas,  D1—D5  (mL  RBCs) 139  ±  191  87  ±  118  0.031
Total drainage  volume  (mL) 489  ±  382 385  ±  302  0.017
Clinical haematomasa 25  (27) 15  (16) 0.108
Homologous  blood  transfusion 8  (8) 3  (3) 0.213
Haemoglobin,  D1  (g/dL)  11.2  ±  1.3  11.9  ±  1.2  <  0.001
Haemoglobin,  D  5  (g/dL)  10.5  ±  1.5  11.4  ±  1.4  <  0.001
Postoperative  management
Fondaparinux  83  (87) 81  (85)  0.833
Antiplatelet  agents  or  effective  anticoagulation  postoperatively 10  (10) 6  (6)  0.434
Side effects
Serum  creatinine  D1  (moL/L)b 78  ±  18  75  ±  23  0.296
Serum creatinine  D5  (moL/L)c 79  ±  18  74  ±  16  0.022
RBCs: red blood cells.
a Data missing for one control and two cases.
b Data missing for 15 patients in each group.
c Data missing for 18 patients in each group.
Table  4  Postoperative  analgesia.
Controls(n  =  95)  Cases(n  =  95)  P
Early  pain
Morphine  use  at  H24  (mg) 12  ±  11 14  ±  12 0.346
Morphine use  at  H48  (mg)  17  ±  14  23  ±  21  0.031
Morphine use  on  D7  (mg)  26  ±  24  35  ±  36  0.029
maxNRS >  3  at  rest  H0-H24  50  (53)  45  (48)  0.562
maxNRS >3  at  rest  H24-H48  12  (13)  14  (15)  0.833
Side effects
Patients  given  ondansetron  by  H24  22  (23)  31  (33)  0.195
Patients given  ondansetron  by  D7  28  (29)  36  (38)  0.283
Patients who  required  bladder  catheterisationa 10  (11)  19  (20)  0.156
Early rehabilitation  therapy
Chair  before  D3a 65  (72)  67  (75)  0.735
Time to  ﬁrst  ambulation  (days)a 3.5  ±  1.2  3.4  ±  1.2  0.604
Delayed pain
maxNRS  >  3  at  rest  on  D30b 22  (29)  22  (29)  1.000
maxNRS >  3  while  walking  on  D30b 36  (48)  32  (43)  0.623
Patients requiring  two  canes  or  a  walker  on  D30b 27  (38)  30  (40)  0.865
maxNRS >  3  at  rest  on  D90—180b 8  (11)  10  (13)  0.802
maxNRS >  3  while  walking  on  D  90—180b 15  (20)  11  (15)  0.518
maxNRS, maximal score on the numeric rating scale for pain in the operated hip
a Data missing for 8 to 14 patients in all.
b Controls: 51 patients evaluated on D180, 24 on D90, and 20 lost to follow-up; cases: 55 patients evaluated on D180, 19 on D90, and
21 lost to follow-up.
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Therefore,  this  effect  does  not  challenge  the  use  of  tranex-
amic  acid,  whose  beneﬁcial  effects  in  terms  of  blood  sparing
far  outweigh  the  small  increase  in  morphine  consumption  on
D7.
Intra-operative  administration  of  tranexamic  acid  during
THA  decreases  total  blood  loss  and  haematoma  volume  but
has  no  effect  on  pain  in  the  early  postoperative  period  or
after  6  months.
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